Methods to assess in vitro drug release from injectable polymeric particulate systems.
about
Preparation of monodisperse biodegradable polymer microparticles using a microfluidic flow-focusing device for controlled drug delivery.Study of the release mechanism of Terminalia chebula extract from nanoporous silica gel.Engineering cells with intracellular agent-loaded microparticles to control cell phenotype.Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation.Accelerated in-vitro release testing methods for extended-release parenteral dosage forms.Drug release from nanomedicines: Selection of appropriate encapsulation and release methodology.5-Fluorouracil-loaded BSA nanoparticles: formulation optimization and in vitro release studyIntegrity of lipid nanocarriers in bloodstream and tumor quantified by near-infrared ratiometric FRET imaging in living miceIn Vitro Dissolution Testing Strategies for Nanoparticulate Drug Delivery Systems: Recent Developments and Challenges.Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition.Development and evaluation of a novel biodegradable sustained release microsphere formulation of paclitaxel intended to treat breast cancer.The nasal delivery of nanoencapsulated statins - an approach for brain deliveryDuel-acting subcutaneous microemulsion formulation for improved migraine treatment with zolmitriptan and diclofenac: formulation and in vitro-in vivo characterization.Spatiotemporal effects of a controlled-release anti-inflammatory drug on the cellular dynamics of host response.Noninvasive fluorescence resonance energy transfer imaging of in vivo premature drug release from polymeric nanoparticles.Critical factors influencing the in vivo performance of long-acting lipophilic solutions--impact on in vitro release method design.Points to consider when establishing drug product specifications for parenteral microspheres.Role of in vitro release models in formulation development and quality control of parenteral depots.Low-molecular-weight heparin (LMWH)-loaded large porous PEG-PLGA particles for the treatment of asthma.Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspectsIn-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing.Nanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity.Product quality for nanomaterials: current U.S. experience and perspective.RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery.Cytotoxicity and in vitro characterization studies of synthesized Jeffamine-cored PAMAM dendrimers.Determining drug release rates of hydrophobic compounds from nanocarriers.A short term quality control tool for biodegradable microspheres.In vitro behavior of poly-lactic-co-glycolic acid microspheres containing minocycline, metronidazole, and ciprofloxacin.Translational studies on a ready-to-use intramuscular injection of penethamate for bovine mastitis.Bioadhesive films containing fluconazole for mucocutaneous candidiasisIn vitro release kinetics of antituberculosis drugs from nanoparticles assessed using a modified dissolution apparatus.Comparison of in vitro dialysis release methods of loperamide-encapsulated liposomal gel for topical drug delivery.IVIVC from Long Acting Olanzapine Microspheres.Development of Risperidone PLGA Microspheres.Assessing the In Vitro Drug Release from Lipid-Core Nanocapsules: a New Strategy Combining Dialysis Sac and a Continuous-Flow System.Comparative study on the suitability of two techniques for measuring the transfer of lipophilic drug models from lipid nanoparticles to lipophilic acceptors.A reproducible accelerated in vitro release testing method for PLGA microspheresFormulation and in vitro characterization of Eudragit® L100 and Eudragit® L100-PLGA nanoparticles containing diclofenac sodium.In vitro dissolution methods for hydrophilic and hydrophobic porous silicon microparticles.FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms.
P2860
Q30480850-8D019ACB-BB49-4B3C-A669-34A42B072324Q34450025-EA145B71-BF01-491A-BB3D-10FBF8B39BBAQ35060703-5A4DAB49-E7FF-4B90-A6DF-3DDCE9EBA436Q35284749-8CE2D849-CAAA-492E-8F0B-06EB9CAE27A8Q36129913-0BBC9FE8-2E43-4CC1-9D07-A1C348900577Q36350400-34B091B1-B86D-4172-9927-467174B7BE22Q37065965-26D05A7A-E316-4F0E-AC94-812D07BDAF9AQ37142585-3481BE28-2D22-4999-A1CA-2FDC0B25AF4EQ37189129-05A4ED72-40BC-4A0F-A251-F9B0D0868C69Q37214483-660119CF-0907-4717-8E1D-8B35CF79E622Q37254496-81BD2C3D-4D0E-4ECF-946D-DE778F29AC0AQ37496394-7F18612E-9D5E-43E0-9802-CC25578782B4Q37601052-73AEC149-E2F8-4552-8152-8AEA5098A593Q37613625-6A76C065-0AE9-425D-9A2B-0E84AEBDFD25Q37624399-34622194-3A1F-4E4A-93DA-292221D21AD2Q37628563-64658240-EA80-41B2-8AEA-BCF6BCB56956Q37634404-B1D64D95-7D99-41CA-8F6C-051BE6B8379DQ37639309-7A566009-189E-40F1-A1C1-0A0CFB4C720FQ37651351-55AA2722-421B-40E3-9146-16E81A465F7BQ37801284-2DE8E76C-A4C2-4229-BE4D-A947974CCDA9Q38017707-FFF2C336-D9C0-4D65-AECA-ED505C510882Q38233071-E94E7387-B7B6-4D30-A9C6-0631BCBA7A27Q38340318-D48FA541-93DB-4F76-A4DE-C6F33B70ABAAQ38728680-2E18478D-F4D0-4968-8BFE-69F871CC8833Q39124574-0E27D457-8323-424F-B710-4A06FFDED92FQ39685483-F9325541-D417-4422-9824-60700D3CB860Q40027648-2408E2AE-ED94-4B08-88A0-AD83B3C4AE5EQ40125974-B361003D-BFC2-4A1B-B630-1C8BD5533A0EQ40209646-0AD8D4C0-A789-44C4-B4F8-D6F10EC43CE5Q41433560-84B80926-12A8-4E19-8DE6-24C92921106CQ41842047-8055A7EA-8C2A-4A72-9288-9556D351698BQ41917770-94A60DCE-B599-4FFF-BFDB-F9076DEF4DA9Q41937906-ABE413A4-7B38-4A42-BEA2-3F312E34E860Q41962765-3C4A702C-C6DF-42A9-8A59-7EB5F562E1E9Q41987489-A3243146-4B42-4455-AF87-2CD59F35E66EQ42075019-73C69347-0916-4F0D-9C5C-6EDD7EF20D06Q42131148-15FA58B7-D578-4225-BE00-E909093DE39DQ42380474-95EE8023-A444-4778-82A5-3B9B427822A0Q42792332-7720B3BA-A6BF-4149-A622-0C36E7F4E079Q42796672-72752C65-757E-4C24-8411-D1B14B7F0C19
P2860
Methods to assess in vitro drug release from injectable polymeric particulate systems.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Methods to assess in vitro drug release from injectable polymeric particulate systems.
@ast
Methods to assess in vitro drug release from injectable polymeric particulate systems.
@en
type
label
Methods to assess in vitro drug release from injectable polymeric particulate systems.
@ast
Methods to assess in vitro drug release from injectable polymeric particulate systems.
@en
prefLabel
Methods to assess in vitro drug release from injectable polymeric particulate systems.
@ast
Methods to assess in vitro drug release from injectable polymeric particulate systems.
@en
P1476
Methods to assess in vitro drug release from injectable polymeric particulate systems.
@en
P2093
Patrick P DeLuca
Susan S D'Souza
P304
P356
10.1007/S11095-005-9397-8
P577
2006-01-13T00:00:00Z